Theriva Biologics, Inc. Share Price & Technical Analysis
TOVX · $0.30 (0.00%)
Healthcare / Biotechnology
$0.30
0.00%
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcino…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
-25% return in May, -29% avg return in past 3 year May month.
75% return in 2026, -81% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 0% | 0% | 0% | 100% | -25% | – | – | – | – | – | – | – | 75% |
| 25 | -24% | 8% | -21% | 27% | -62% | -20% | 0% | -20% | 0% | -25% | 0% | -33% | -170% |
| 24 | 16% | -9% | 3% | -15% | -35% | -3% | -3% | 7% | -75% | 7% | -36% | 38% | -106% |
| 23 | 82% | -2% | -20% | -16% | 9% | 45% | -33% | -22% | -4% | -14% | 34% | -27% | 32% |
| 22 | -7% | -4% | 21% | -20% | -8% | -5% | -28% | 3% | -33% | -24% | -9% | -36% | -150% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) for multiple gastrointestinal and metabolic indications. In addition, it develops clinical stage products, such as SYN-006 to prevent aGVH, clostridioides difficile infection, and microbiome damage in patients treated with carbapenem antibiotics; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. The company has a license agreement with Rasayana Therapeutics, Inc. to research, develop, manufacture, and commercialize any product that includes SYN-020, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$15.34M
P/E ratio
—
52W high
$0.86
52W low
$0.16
Volume
9,08,375
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Theriva Biologics, Inc. share price today?
- Theriva Biologics, Inc. (TOVX) last traded around $0.30 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does TOVX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for TOVX. Download the app for real-time alerts.
- How can I analyze Theriva Biologics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.